To view the fulltext, please log in
To view the pdf, please log in
Copyright / Drug Dosage
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
- Bhagwagar Z, Rabiner EA, Sargent PA, Grasby PM, Cowen PJ: Persistent reduction in brain serotonin-1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Mol Psychiatry 2004;9:386-392.
- Meltzer CC, Price JC, Mathis CA, et al: Serotonin 1A receptor binding and treatment response in late-life depression. Neuropsychopharmacology 2004;29:2258-2265.
- Karlsson H, Hirvonen J, Kajander J, Markkula J, Rasi-Hakala H, Salminen JK, Någren K, Aalto S, Hietala J: Research letter: Psychotherapy increases brain serotonin 5-HT1A receptors in patients with major depressive disorder. Psychol Med 2010;40:523-528.
- Salminen JK, Karlsson H, Hietala J, Kajander J, Aalto S, Markkula J, Rasi-Hakala H, Toikka T: Short-term psychodynamic psychotherapy and fluoxetine in major depressive disorder: a randomized comparative study. Psychother Psychosom 2008;77:351-357.
- Marston OJ, Garfield AS, Heisler LK: Role of central serotonin and melanocortin systems in the control of energy balance. Eur J Pharmacol 2011;660:70-79.
- Hollon SD, DeRubeis RJ, Shelton RC, et al: Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Arch Gen Psychiatry 2005;62:417-422.
- Andrews PW, Kornstein SG, Halberstadt LJ, Gardner CO, Neale MC: Blue again: perturbational effects of antidepressants suggest monoaminergic homeostasis in major depression. Front Psychol 2011;2:1-24.
- Bech P: Social functioning: should it become an endpoint in trials of antidepressants? CNS Drugs 2005;19:313-324.